Zealand and Roche report positive Phase 2 results for amylin drug petrelintide in obesity and diabetes
Zealand Pharma and Roche announced topline results from a Phase 2 trial of their amylin analogue petrelintide in patients with obesity and type 2 diabetes.
The interim data showed that participants receiving petrelintide experienced reductions in body weight and improvements in glycemic control compared with baseline. No safety concerns were highlighted.
The companies view the findings as a step toward positioning the drug against Eli Lilly’s amylin programs, which dominate the market.
The data will be presented at an upcoming scientific meeting and will guide the design of a larger pivotal trial.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that